Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. [electronic resource]
Producer: 20191028Description: 615-622 p. digitalISSN:- 1365-2133
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Candida albicans -- immunology
- Candidiasis -- epidemiology
- Cardiovascular Diseases -- chemically induced
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Dose-Response Relationship, Drug
- Etanercept -- administration & dosage
- Female
- Humans
- Immunosuppressive Agents -- administration & dosage
- Inflammatory Bowel Diseases -- epidemiology
- Interleukin-23 Subunit p19 -- antagonists & inhibitors
- Male
- Middle Aged
- Placebos -- administration & dosage
- Psoriasis -- diagnosis
- Randomized Controlled Trials as Topic
- Severity of Illness Index
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.